Real-world overall survival of patients with chronic lymphocytic leukemia treated with frontline Bruton tyrosine kinase inhibitors: an analysis of a large US multi-payer claims database

ASH 2026 • CLL/SLL • Zanubrutinib • Poster

Guru Subramanian Guru Murthy, MD MS

DISCLAIMER

The contents of the presentation are designed for educational and scientific exchange purposes and are not promotional. They may contain information on investigational products or investigational uses of approved products. No conclusions regarding safety and/or efficacy for such investigational products or uses may be made.

SUMMARY

This retrospective cohort study used PurpleLab CLEAR multi-payer claims data to compare real-world overall survival (rwOS) among adults with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) initiating first-line covalent Bruton tyrosine kinase inhibitor monotherapy. A total of 23,168 eligible patients initiated first-line zanubrutinib (n=5,893), acalabrutinib (n=9,423), or ibrutinib (n=7,852) between January 2020 and February 2026 (data cutoff: May 29, 2026). Median follow-up was 17 months among patients treated with zanubrutinib compared with 24 months for patients receiving acalabrutinib and 36 months for ibrutinib, consistent with regulatory milestones. Median rwOS was not reached in any treatment group during the follow-up. Zanubrutinib-treated patients had higher survival probabilities at 24 months (86.8% [95% CI: 85.5-88.2]) and 36 months (83.1% [95% CI: 81.3-84.9]) compared with acalabrutinib (83.1% [95% CI: 82.2-83.9] and 77.3% [95% CI: 76.2-78.3]) and ibrutinib (81.3% [95% CI: 80.2-82.5] and 75.0% [95% CI: 73.7-76.3]), respectively. In crude and inverse probability of treatment weighting (IPTW)-weighted analyses, zanubrutinib was associated with significantly lower all-cause mortality versus acalabrutinib (crude hazard ratio [HR], 0.81 [95% CI, 0.74-0.88]; IPTW- weighted HR, 0.75 [95% CI, 0.67-0.84]; P<0.0001) and ibrutinib (crude HR, 0.67 [95% CI, 0.61-0.72]; IPTW-weighted HR, 0.68 [95% CI, 0.60-0.77]; P<0.0001). Results were generally consistent across all subgroups, except for patients aged <65 years, which was the smallest subgroup and may have been underpowered. In addition, because this is a nonrandomized claims analysis with different follow-up durations and potential residual confounding, associations should not be interpreted as causal treatment effects.

Population Intervention / Exposure Comparator Outcomes
Adults with chronic lymphocytic leukemia/small lymphocytic lymphoma in the PurpleLab CLEAR US multi-payer claims database who initiated first-line covalent Bruton tyrosine kinase inhibitor monotherapy between January 2020 and February 2026 Zanubrutinib Acalabrutinib or ibrutinib Real-world overall survival, 24- and 36-month survival probabilities, all-cause mortality. Prespecified subgroup analyses by age, sex, and Charlson Comorbidity Index

FAQs

This study compared real-world overall survival (rwOS) among patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) initiating first-line covalent Bruton tyrosine kinase inhibitor (cBTKi) monotherapy with zanubrutinib, acalabrutinib, or ibrutinib using the PurpleLab CLEAR claims database.

This retrospective cohort study used PurpleLab CLEAR claims data, which included open and closed medical and pharmacy claims across commercial, Medicare, and Medicaid coverage. Eligible adult patients with CLL/SLL (≥2 CLL/SLL diagnostic codes on ≥2 distinct dates) who initiated first-line cBTKi monotherapy with zanubrutinib, acalabrutinib, or ibrutinib between January 2020 and February 2026 were included (data cutoff: May 29, 2026). Mortality data were assessed and linked across multiple data sources. Median real-world overall survival (rwOS) and survival probabilities at 24 and 36 months were estimated using the Kaplan-Meier method. Hazard ratios and 95% CIs were estimated using crude and inverse probability of treatment weighting (IPTW)-weighted Cox proportional hazards models, with IPTW using stabilized weights derived from a multinomial propensity score model based on index year, age, sex, Charlson Comorbidity Index (CCI), geographic region, and race/ethnicity. Prespecified subgroup analyses were conducted by age, sex, and CCI.

A total of 23,168 patients met eligibility criteria, including 5,893 treated with zanubrutinib, 9,423 with acalabrutinib, and 7,852 with ibrutinib. Median age overall was 75 years (interquartile range [IQR], 69-80). Medicare was the most common payer (55.7%), followed by commercial insurance (35.0%). Most patients were male (60.5%) and Non-Hispanic White (61.5%), with a median CCI of 3. The most common baseline comorbidities were hypertension (68.6%) and diabetes (29.9%). Median follow-up was 17 months for zanubrutinib, 24 months for acalabrutinib, and 36 months for ibrutinib, consistent with regulatory approval milestones.

During follow-up, 5,200 deaths were recorded. Median rwOS was not reached in any treatment group. Zanubrutinib-treated patients had higher survival probabilities at 24 months (86.8%; 95% CI, 85.5-88.2) and 36 months (83.1%; 95% CI, 81.3-84.9) compared with acalabrutinib (83.1% [95% CI, 82.2-83.9] and 77.3% [95% CI, 76.2-78.3]) and ibrutinib (81.3% [95% CI, 80.2-82.5] and 75.0% [95% CI, 73.7-76.3]; all P<0.0001).

 

In both crude and IPTW-weighted analyses, zanubrutinib was associated with significantly lower all-cause mortality versus acalabrutinib (crude HR, 0.81 [95% CI, 0.74-0.88]; weighted HR, 0.75 [95% CI, 0.67-0.84]; P<0.0001) and ibrutinib (crude HR, 0.67 [95% CI, 0.61-0.72]; weighted HR, 0.68 [95% CI, 0.60-0.77]; P<0.0001).

Results were generally consistent across prespecified subgroups, except for age <65 years which was the smallest subgroup and may have been underpowered. Zanubrutinib was associated with better survival than acalabrutinib among patients aged 65-74 years (weighted HR, 0.69 [95% CI, 0.52-0.92]), aged ≥75 years (weighted HR, 0.74 [95% CI, 0.65-0.84]), with CCI ≤3 (weighted HR, 0.67 [95% CI, 0.55-0.81]), and CCI >3 (weighted HR, 0.79 [95% CI, 0.69-0.92]). Similarly, zanubrutinib was associated with better survival than ibrutinib among patients aged 65-74 years (weighted HR, 0.64 [95% CI, 0.48-0.86]), aged ≥75 years (weighted HR, 0.67 [95% CI, 0.59-0.77]), with CCI ≤3 (weighted HR, 0.58 [95% CI, 0.48-0.70]), and CCI >3 (weighted HR, 0.74 [95% CI, 0.63-0.86]).

The authors noted that the study period overlapped with the COVID-19 pandemic, which may limit generalizability of findings to other time periods.

You are now leaving the website

This link is provided for information purposes only. You’ll be leaving beonemedaffairs.com and accessing a third-party website over which [BeOne Medicines | GmbH] has no control or influence.

This link will take you to a third-party website outside of beonemedaffairs.com.

[BeOne Medicines | GmbH] has no control over this website and makes no representations regarding its content or availability in your location. [BeOne Medicines | GmbH] declines any responsibility for third-party information, data usage policies, or personal data processing.

By proceeding, you acknowledge that you are part of the intended audience of the third-party website and confirm your compliance with applicable laws.

Do you want to leave beonemedaffairs.com

You are now leaving the website beonemedaffairs.com and entering another BeOne website with different terms of use. Information included on this website may not be specific to your country. Click Continue to proceed